← 홈

ADC

167개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 167개
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-AVD-R 1 and 2: COHORT IIa (Bv-AVD-R 1 and 2: COHORT IIa)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NAVD-R, Cycle 1-2 (Bv-NAVD-R, Cycle 1-2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-2 (Bv-NVD-R, Cycle 1-2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-4 RER (Bv-NVD-R, Cycle 1-4 RER)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Bv-NVD-R, Cycle 1-4 SER (Bv-NVD-R, Cycle 1-4 SER)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleCStone PharmaceuticalsPhase 1

CS5001 (CS5001)

Advanced Solid Tumor; Advanced Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

DOC Group C (DOC Group C)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

R (Dacarbazine, Dacarbazine(R))

Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma · Stage II Childhood Hodgkin Lymphoma

#StageIIChildhoodHodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0.444%임상시험 1상태 RECRUITING
ADCBiologicstaleSeagen Inc.Preclinical

Doxorubicin HCL (Doxorubicin HCL)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleGenmabPhase 2

Doxorubicin Hydrochloride [HCl] (Doxorubicin Hydrochloride [HCl])

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleChinese PLA General HospitalPhase 2

Eliglustat, CD30 target immunotherapy (Eliglustat, CD30 target immunotherapy)

Lymphoma · CD30

#CD30#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Fexagratinib (Fexagratinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy)

Aggressive B-Cell Lymphoma · Aggressive B-Cell Lymphoma

#AggressiveB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone (Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone)

DLBCL - Diffuse Large B Cell Lymphoma; Chemo-free Therapy · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

Hi-miniCHOP +orelabrutinib (Hi-miniCHOP +orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

HiMTO (HiMTO)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerApproved

Inotuzumab ozogamicin-dose level 1 (Inotuzumab ozogamicin-dose level 1)

Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia

#Leukemia#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleNovartis PharmaceuticalsPhase 1

JBH492 (JBH492)

Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleNew York Medical CollegePhase 2

MAD CPR 1 and 2 (MAD CPR 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING

7 / 9 페이지

← 이전다음 →